A study of over 450,000 NSTEMI admissions reveals that diabetics face disparities in care, with less invasive treatment ...

A study uncovers IL-1β signaling in cardiac fibrosis, highlighting distinct fibroblast populations and promising ...

There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

Obesity Hypoventilation Syndrome (OHS) is associated with worse clinical outcomes in hospitalized patients with STEMI or NSTEMI.

The Global Myocardial Infarction Therapeutics Market is estimated to be valued at USD 15.56 billion in 2023 and is projected to grow at a CAGR of 4.19% over the forecast period 2024-2032. Read the ...

A new cell therapy, targeting CD7 in leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment ...

A safe and effective point-of-care test can be used to speed up the diagnosis or ruling out of myocardial infarction, a new ...

The global creatine kinase reagent market, valued at approximately USD 296.2 million at the end of 2021, is poised for substantial growth, with projections indicating a compound annual growth rate ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug ...

With a 10-minute time to first result, the Atellica IM TnIH test now can be used as an aid in prognosis for 30-, 90-, 182-, and 365-day all-cause mortality and major adverse cardiac events (MACE) in ...